— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
After starting the week on a positive note, major stock indexes witnessed volatility and slipped mid-week. Meanwhile, the S&P 500 index regained a part of the lost momentum and closed
The TJX Companies Inc. (NYSE: TJX) saw sales slightly drop during the third quarter of 2021 while earnings benefited from lower tax rates. Open-only comp store sales were down 5%
Value investors have long viewed the fintech industry as a gold mine of opportunities in the years to come, with payment processing services carrying a fair share of interest. Those